German dialysis products and services company Fresenius Medical Care has completed the $2bn acquisition of US-based medical devices maker NxStage Medical, after receiving clearance from the US antitrust authorities.

NxStage Medical primarily focuses on the development, production and marketing of medical devices for in-home dialysis and critical care.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The deal, first announced in August 2017, will help Fresenius Medical Care leverage its manufacturing, supply chain and marketing capabilities across the dialysis products, services and Care Coordination businesses.

“NxStage Medical’s portfolio includes the portable haemodialysis system called NxStage System One, which has been cleared by the US Food and Drug Administration (FDA) for home use.”

Fresenius Medical Care CEO Rice Powell said: “By combining NxStage’s capabilities with our broad product and service offering, we can help patients to live even more independently.

“In addition to broadening our product portfolio, this acquisition positions Fresenius Medical Care to benefit from the growing trend toward home-based therapies.”

Founded in 1998, NxStage Medical employs nearly 3,800 people globally. The company generated $394m in revenue in 2017.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Its portfolio includes the portable haemodialysis system called NxStage System One, which has been cleared by the US Food and Drug Administration (FDA) for home use.

Commenting on the deal, Fresenius Medical Care North America CEO Bill Valle noted: “With their strong culture of innovation and transformation, they will help us to realise our vision of delivering access to superior patient care and outcomes in a lower-cost-of-care home setting to all the patients we care for.”

Recently, medical products firm B. Braun Medical acquired the Medisystems Streamline Bloodlines business of NxStage Medical for an undisclosed amount.

The acquired products include Streamline Bloodline for Dialog+ haemodialysis system and the Fresenius Medical Care haemodialysis system, along with the Streamline Bloodline Long for the Fresenius Medical Care haemodialysis system.

This addition of Streamline bloodline products expands B. Braun Medical’s dialysis products portfolio.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact